Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov 9:17:e22.
doi: 10.15420/ecr.2022.30. eCollection 2022 Feb.

Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation

Akira Matsumori  1
Affiliations
Review

Management of Atrial Fibrillation Using Immunoglobulin Free Light Chains, Novel Biomarkers of Inflammation

Akira Matsumori. Eur Cardiol. .

Abstract

AF is the most common cardiac arrhythmia. There is growing evidence that inflammatory mechanisms play an important role in its pathogenesis; inflammasome activation contributes to the onset and progression of AF. An increase in NOD-like-receptor-pyrin domain-containing-3 (NLRP3) inflammasome activation releases proinflammatory cytokines that activate nuclear factor (NF)-κB, which regulates the production of immunoglobulin free light chains (FLCs). Serum FLC levels are increased in patients with AF, and FLCs are biomarkers of inflammation. Inflammasomes and NF-κB may be targets for anti-inflammatory strategies to prevent and treat AF when FLC levels are elevated. This review discusses the role of inflammation in the pathogenesis of AF, as well as FLCs as novel inflammatory biomarkers for the management of AF.

Keywords: Atrial fibrillation; biomarker; immunoglobulin; inflammasome; inflammation; light chains; myocarditis.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The author has no conflicts of interest to declare.

Figures

Figure 1:
Figure 1:. Immunoglobulin Free Light Chains as Inflammatory Biomarkers of AF
Figure 2:
Figure 2:. AF in a Mouse Model of Encephalomyocarditis Virus Myocarditis
Figure 3:
Figure 3:. FLCs in Patients With Lone AF and Age-matched Normal Volunteers
See this image and copyright information in PMC

References

    1. Kugler S, Onodi Z, Ruppert M et al. Inflammasome activation in end-stage heart failure-associated atrial fibrillation. ESC Heart Fail. 2022;9:2747–52. doi: 10.1002/ehf2.13972. - DOI - PMC - PubMed
    1. Sagris M, Vardas EP, Theofilis P et al. Atrial fibrillation: pathogenesis, predisposing factors, and genetics. Int J Mol Sci. 2021;23:6. doi: 10.3390/ijms23010006. - DOI - PMC - PubMed
    1. Gawalko M, Salijic A, Li N Adiposity-associated atrial fibrillation: molecular determinants, mechanisms and clinical significance. Cardiovasc Res. 2022. epub ahead of press. - DOI - PMC - PubMed
    1. Brundel BJJM, Ai X, Hills MT et al. Atrial fibrillation. Nat Rev Dis Primers. 2022;8:21. doi: 10.1038/s41572-022-00347-9. - DOI - PubMed
    1. Ajoolabagy A, Nattel S, Lip GYH, Ren J. Inflammasome signaling in atrial fibrillation: JACC state-of-the-art review. J Am Coll Cardiol. 2022;79:2349–66. doi: 10.1016/j.jacc.2022.03.379. - DOI - PMC - PubMed

LinkOut - more resources